Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.53 |
| ▸ | UNG | P13051 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 2/20 | 0.49 |
| ▸ | P4HB | P07237 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | BID | P55957 | 3/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | BAK1 | Q16611 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290447 | 1.00 | TTR (0.53) | TTRUNGFBP1STSP4HB | |
| SCHEMBL2817107 | 1.00 | TTR (0.53) | TTRUNGFBP1STSP4HB | |
| Acetic Acid SCHEMBL11384341 | 0.97 | TTR (0.50) | TTRUNGFBP1STSP4HB | |
| SCHEMBL9506061 | 0.94 | STS (0.51) | TTRUNGFBP1STSP4HB | |
| SCHEMBL9504789 | 0.94 | STS (0.51) | TTRUNGFBP1STSP4HB | |
| SCHEMBL9504784 | 0.94 | STS (0.51) | TTRUNGFBP1STSP4HB | |
| SCHEMBL6560953 | 0.88 | PDE5A (0.42) | TTRUNGFBP1STSPDE5A | |
| SCHEMBL20810556 | 0.87 | FAAH (0.46) | STSKMT2APDE5AALDH1A1CYP1A2 | |
| SCHEMBL13064621 | 0.84 | P4HB (0.53) | P4HBKMT2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL880074 | 0.84 | TTR (0.58) | TTRUNGFBP1STSP4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689849-B1 | PERFUME PRECURSOR | TAKASAGO PERFUMERY CO LTD (JP) | 2025-01-15 | — | — | EP | claimed |
| US-8968452-B2 | Phase change inks containing crystalline trans-cinnamic diesters and amorphous isosorbide oligomers | XEROX CORPORATION (US) | 2015-03-03 | — | — | US | claimed |
| US-8841055-B2 | Super low melt emulsion aggregation toners comprising a trans-cinnamic di-ester | XEROX CORPORATION (US) | 2014-09-23 | — | — | US | claimed |
| US-8778069-B2 | Phase change inks containing oligomeric rosin esters | XEROX CORPORATION (US) | 2014-07-15 | — | — | US | claimed |
| US-20140137767-A1 | Phase Change Inks Containing Oligomeric Rosin Esters | XEROX CORPORATION (US) | 2014-05-22 | — | — | US | claimed |
| US-20130266896-A1 | SUPER LOW MELT EMULSION AGGREGATION TONERS COMPRISING A TRANS-CINNAMIC DI-ESTER | XEROX CORPORATION (US) | 2013-10-10 | — | — | US | claimed |
| US-20130131226-A1 | Phase Change Inks Containing Crystalline Trans-Cinnamic Diesters and Polyterpene Resins | XEROX CORPORATION (US) | 2013-05-23 | — | — | US | claimed |
| US-20130032056-A1 | Phase Change Inks Containing Crystalline Trans-Cinnamic Diesters and Amorphous Isosorbide Oligomers | XEROX CORPORATION (US) | 2013-02-07 | — | — | US | claimed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-9938221-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2427416-B1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| EP-0021100-B1 | CYCLOHEXENES ON THEIR OWN OR MIXED WITH (IV), PROCESS FOR PREPARATION OF (I), USE OF (I), OPTIONALLY (I+IV), AS AROMATIC AND/OR PERFUMERY SUBSTANCES, AND COMPOSITIONS OF AROMATIC AND/OR PERFUMERY SUBSTANCES THAT CONTAIN (I), OPTIONALLY (I+IV) | L. GIVAUDAN & CIE Société Anonyme (CH) | 1982-11-17 | — | — | EP | disclosed |
| EP-0045453-A1 | Alkenols (I) and process for their preparation, utilisation of (I) as fragrants and/or aromatic compounds, as well as a fragrant and/or aromatic composition containing (I) | L. GIVAUDAN & CIE Société Anonyme (CH) | 1982-02-10 | — | — | EP | disclosed |
| EP-0011877-B1 | CARANE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS PERFUMES, AND PERFUME COMPOSITIONS CONTAINING THEM | L. Givaudan & Cie Société Anonyme (CH) | 1981-05-20 | — | — | EP | disclosed |
| EP-0024306-A2 | Substituted tetralines and indanes (I), use of (I) as perfuming and/or flavouring agents, and perfuming and/or flavouring compositions containing (I) | L. Givaudan & Cie Société Anonyme (CH) | 1981-03-04 | — | — | EP | disclosed |
| EP-0021100-A1 | Cyclohexenes on their own or mixed with (IV), process for preparation of (I), use of (I), optionally (I+IV), as aromatic and/or perfumery substances, and compositions of aromatic and/or perfumery substances that contain (I), optionally (I+IV) | L. GIVAUDAN & CIE Société Anonyme (CH) | 1981-01-07 | — | — | EP | disclosed |
| EP-0011877-A1 | Carane derivatives, process for their preparation, their use as perfumes, and perfume compositions containing them | L. Givaudan & Cie Société Anonyme (CH) | 1980-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TYR, PAH, REN | TTR 220/4885UNG 2046/4885FBP1 1449/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | TTR 220/4885UNG 2046/4885FBP1 1449/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | TTR 220/4885UNG 2046/4885FBP1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.